Wuh-Liang (“Paul”) Hwu

Title: Wuh-Liang (“Paul”) Hwu: Innovator in Gene Therapy

Introduction

Wuh-Liang (“Paul”) Hwu is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of gene therapy, particularly in the treatment of aromatic-amino acid decarboxylase (AADC) deficiency. With a total of 3 patents, his work is paving the way for innovative therapeutic solutions.

Latest Patents

One of Hwu's latest patents focuses on gene therapy for AADC deficiency. This invention outlines compositions and methods for treating this condition, particularly in pediatric subjects. The method involves providing a pharmaceutical formulation that includes an rAAV2-hAADC vector and delivering it stereotactically to targeted sites in the brain. The dosage is specified to be at least about 1.8×10^vg, with options for frameless stereotaxy. Additionally, the invention discusses the potential administration of a dopamine-antagonist, such as risperidone, to enhance treatment efficacy.

Career Highlights

Hwu has worked with notable institutions, including National Taiwan University and PTC Therapeutics, Inc. His experience in these organizations has contributed to his expertise in gene therapy and innovative treatment methodologies.

Collaborations

Some of Hwu's coworkers include Mark Pykett and Richard M. Thorn. Their collaboration has likely fostered advancements in the research and development of gene therapies.

Conclusion

Wuh-Liang (“Paul”) Hwu is a key figure in the field of gene therapy, with a focus on treating AADC deficiency. His innovative approaches and collaborations are instrumental in advancing medical science and improving patient outcomes.